AZ India Unit Votes To Delist From Local Stock Exchanges
This article was originally published in PharmAsia News
AstraZeneca Pharma India's board voted in favor of taking itself off the India stock exchanges as requested by the parent, UK-headquartered AstraZeneca Pharmaceutical, after it acquired 75% of the India subsidiary.
You may also be interested in...
The rare disease-focused firm will pay $90m up front to acquire Orphan Technologies and its Phase I/II enzyme replacement therapy for homocystinuria. Earnouts up to $427m are possible as well.
Investors in surgical robotics company Auris say Johnson & Johnson failed to support the company per their merger agreement.